WallStSmart

Canton Strategic Holdings, Inc. (CNTN)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 3789792% more annual revenue ($56.69B vs $1.50M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

CNTN

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 6.3
Piotroski: 3/9Altman Z: 1.54

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CNTN.

NVSSignificantly Overvalued (-50.3%)

Margin of Safety

-50.3%

Fair Value

$93.40

Current Price

$140.37

$46.97 premium

UndervaluedFair: $93.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNTN1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

CNTN4 concerns · Avg: 3.8/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.544/10

Distress zone — elevated risk

Market CapQuality
$167.33M3/10

Smaller company, higher risk/reward

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CNTN

The strongest argument for CNTN centers on Price/Book.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : CNTN

The primary concerns for CNTN are Revenue Growth, EPS Growth, Altman Z-Score.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

CNTN carries more volatility with a beta of 1.50 — expect wider price swings.

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 26/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Canton Strategic Holdings, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Canton Strategic Holdings, Inc. (CNTN) operates as a diversified investment firm focused on maximizing shareholder value through strategic acquisitions and the management of a diverse asset portfolio across multiple sectors. With an emphasis on value-driven investments and operational efficiencies, CNTN is strategically positioned to leverage emerging market opportunities and propel sustainable growth. The company’s robust approach to strategic planning and investment execution aims to deliver superior returns while effectively navigating the complexities of the financial landscape, making it an attractive option for institutional investors seeking stability and growth potential.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?